...
首页> 外文期刊>Taiwanese journal of obstetrics and gynecology >Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2eu status in Taiwanese breast cancer patients.
【24h】

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2eu status in Taiwanese breast cancer patients.

机译:台湾乳腺癌患者中HER-2 / neu状况​​的免疫组化和荧光原位杂交评估的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Accurate diagnostic assessment of human epidermal growth factor receptor-2 (HER-2) is essential and a prerequisite for appropriate application of the humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin) to the treatment of patients with breast cancer. Immunohistochemistry (IHC) is the most widely applicable diagnostic modality in studying HER-2 status. Fluorescence in situ hybridization (FISH) is also recognized as a modality in cases with an equivocal IHC status (score, 2+). Some authors claimed that FISH alone is sufficient. The aim of this study was to correlate the test results of IHC and FISH for HER-2 gene amplification in breast cancer patients. FISH for topoisomerase IIalpha (TOP2A) was also studied to see if deletion or amplification of TOP2A has any supplementary role to HER-2, FISH and IHC. MATERIALS AND METHODS: Assessment of HER-2 gene amplification and TOP2A gene amplification/deletion was made by FISH analysis using the LSI TOP2A/HER-2/CEP 17 multicolor probe or the LSI HER-2/CEP dual color probe (Vysis, Downers Grove, IL, USA) in formalin-fixed and paraffin-embedded tissue sections of 54 breast cancer patients who were grouped into stages 1+, 2+ or 3+ based on IHC (HercepTest; DakoCytomation, Carpinteria, CA, USA) observations. RESULTS: None of IHC 1+ breast tumors was HER-2 FISH positive, but three of 18 (17%) IHC 3+ tumors were HER-2 FISH negative. Overall, 53% of the IHC 2+ and 83% of the IHC 3+ cases were HER-2 FISH positive. Only one case with IHC 3+ tumor that was HER-2 FISH positive was found to have TOP2A amplification (>2.0) and no IHC 2+ cases were found to have TOP2A amplification. There were no cases with TOP2A deletion (<0.8) in our whole series. There were also no cases of HER-2 FISH negative tumors, but IHC scored as 2+ or 3+ (0 of 10), to be found with TOP2A amplification. The discordance rates by IHC were high (46.7% in IHC 2+, 16.7% in IHC 3+, 30.3% overall in IHC 2+ or 3+). On the contrary, the discordance rates were zero if by FISH. CONCLUSION: The current algorithm to use HER-2 FISH as a supplementary role to IHC HercepTest 2+ may need some modifications according to the local setting. TOP2A FISH adds little value to HER-2 FISH and IHC staining in our study.
机译:目的:对人表皮生长因子受体2(HER-2)的准确诊断评估对于将人源化抗HER-2单克隆抗体曲妥珠单抗(赫赛汀)正确应用于乳腺癌患者的治疗是必不可少的前提。免疫组织化学(IHC)是研究HER-2状态最广泛应用的诊断方法。荧光原位杂交(FISH)在IHC状态不明确的情况下(评分2+)也被认为是一种治疗方式。一些作者声称仅FISH就足够了。这项研究的目的是关联IHC和FISH在乳腺癌患者中HER-2基因扩增的测试结果。还对拓扑异构酶IIalpha(TOP2A)的FISH进行了研究,以了解TOP2A的缺失或扩增是否对HER-2,FISH和IHC具有补充作用。材料与方法:使用LSI TOP2A / HER-2 / CEP 17多色探针或LSI HER-2 / CEP双色探针(Vysis,Downers)通过FISH分析对HER-2基因扩增和TOP2A基因扩增/缺失进行评估。根据IHC(HercepTest; DakoCytomation,Carpinteria,CA,USA)观察,将54名乳腺癌患者的福尔马林固定和石蜡包埋的组织切片分为1 +,2 +或3+期。结果:IHC 1+乳腺肿瘤均未出现HER-2 FISH阳性,但18例IHC 3+乳腺肿瘤中有3例(HER-2 FISH)呈阴性。总体而言,IHC 2+病例中53%和IHC 3+病例中83%为HER-2 FISH阳性。仅发现1例HER-2 FISH阳性的IHC 3+肿瘤具有TOP2A扩增(> 2.0),没有发现IHC 2+肿瘤具有TOP2A扩增。在我们的整个系列中,没有TOP2A缺失的病例(<0.8)。也没有HER-2 FISH阴性肿瘤的病例,但通过TOP2A扩增发现IHC得分为2+或3+(10个中的0个)。 IHC的不一致率很高(IHC 2+中为46.7%,IHC 3+中为16.7%,IHC 2+或3+中总体为30.3%)。相反,如果采用FISH,则不一致率为零。结论:当前使用HER-2 FISH作为IHC HercepTest 2+的补充角色的算法可能需要根据本地设置进行一些修改。在我们的研究中,TOP2A FISH对HER-2 FISH和IHC染色几乎没有价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号